St. John's Wort Extract LI 160 for the Treatment of Atypical Depression

Atypical Depression Clinical Trial

Status Completed

Clinical Trial Summary

The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.

Clinical Trial Description

The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reversed vegetative signs, such as hyperphagia or hypersomnia, is traditionalla neglected, demonstrated by the fact that in the most widely used depression scales, such as the Hamilton Depression Scale, melancholic symptoms have a specific weight, while, by contrast, reversed vegetative signs are not included. This etablishes a tendency to underestimate the severity of atypical depression. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atypical Depression
• Depression
• Depressive Disorder

• NCT number: NCT00861978
• Study type: Interventional
• Source: Cassella-med GmbH & Co. KG
• Status: Completed
• Phase: Phase 3
• Start date: December 2002
• Completion date: November 2004